MURALI CHINTAGUMPALA to Cohort Studies
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Cohort Studies.
Connection Strength
0.107
-
Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020 02; 139(2):259-271.
Score: 0.022
-
Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatr Blood Cancer. 2020 02; 67(2):e28064.
Score: 0.022
-
Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. J Clin Oncol. 2020 01 01; 38(1):43-50.
Score: 0.022
-
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
Score: 0.019
-
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15.
Score: 0.016
-
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 2001 Jul 22; 102(1):11-7.
Score: 0.006